(VIANEWS) – Shares of Xenetic Biosciences (NASDAQ: XBIO) rose by a staggering 27.69% in 10 sessions from $3.07 at 2023-06-29, to $3.92 at 11:53 EST on Friday, following the last session’s downward trend. NASDAQ is jumping 0.36% to $14,188.91, after four sequential sessions in a row of gains.
Xenetic Biosciences’s last close was $4.00, 60% below its 52-week high of $10.00.
About Xenetic Biosciences
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. In addition, the company leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, and PJSC Pharmsynthez. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Earnings Per Share
As for profitability, Xenetic Biosciences has a trailing twelve months EPS of $-3.9.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -39.06%.
Volume
Today’s last reported volume for Xenetic Biosciences is 1471 which is 95.64% below its average volume of 32581.
Volatility
Xenetic Biosciences’s last week, last month’s, and last quarter’s current intraday variation average was 7.14%, 1.49%, and 4.87%.
Xenetic Biosciences’s highest amplitude of average volatility was 8.92% (last week), 4.37% (last month), and 4.87% (last quarter).
Previous days news about Xenetic Biosciences (XBIO)
- Xenetic biosciences (xbio) upgraded to strong buy: what does it mean for the stock?. According to Zacks on Thursday, 13 July, "Therefore, the Zacks rating upgrade for Xenetic Biosciences basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.", "Investors might want to bet on Xenetic Biosciences (XBIO Quick QuoteXBIO – Free Report) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). "
More news about Xenetic Biosciences (XBIO).
